Compare · AKYA vs BRKR
AKYA vs BRKR
Side-by-side comparison of Akoya BioSciences Inc. (AKYA) and Bruker Corporation (BRKR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKYA and BRKR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $9.72B, about 25.0x AKYA ($388.8M).
- Over the past year, AKYA is up 11.1% and BRKR is up 65.8% - BRKR leads by 54.7 points.
- BRKR has hit the wire 11 times in the past 4 weeks while AKYA has been quiet.
- BRKR has more recent analyst coverage (22 ratings vs 13 for AKYA).
- Company
- Akoya BioSciences Inc.
- Bruker Corporation
- Price
- $1.30-5.80%
- $62.69+9.29%
- Market cap
- $388.8M
- $9.72B
- 1M return
- +11.11%
- +72.25%
- 1Y return
- +11.11%
- +65.80%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 11
- Recent ratings
- 13
- 22
Akoya BioSciences Inc.
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. It provides two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational, and clinical research. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Latest AKYA
- SEC Form 15-12G filed by Akoya BioSciences Inc.
- SEC Form EFFECT filed by Akoya BioSciences Inc.
- Director Mendel Scott disposed of 28,500 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Ramachandran Niro Ph.D acquired 62,566 shares, covered exercise/tax liability with 42,148 shares and disposed of 282,555 shares, closing all direct ownership in the company (SEC Form 4)
- President and CEO Mckelligon Brian disposed of 947,688 shares, acquired 724,428 shares and covered exercise/tax liability with 196,866 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Legal Officer Kamocsay Jennifer disposed of 179,272 shares, closing all direct ownership in the company (SEC Form 4)
- CFO Ek John Frederick disposed of 268,202 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Clinical Officer Bamford Pascal disposed of 205,738 shares, closing all direct ownership in the company (SEC Form 4)
- Director Winkler Matthew disposed of 984,513 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Shepler Robert G
Latest BRKR
- Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
- Wolfe Research resumed coverage on Bruker
- Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
- SEC Form SD filed by Bruker Corporation
- Amendment: Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
- Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Bernard Thierry was granted 2,886 shares (SEC Form 4)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $87,800 worth of shares (2,000 units at $43.90) as part of a pre-agreed trading plan (SEC Form 4)
- Bruker Corporation filed SEC Form 8-K: Other Events